1MIYAKIS S, LOCKSHIN M D, ATSUMI T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J].J Thromb Haemost,2006,4(2):295-306.
6[1]MIYAKIS S,LOCKSHIN MD,ATSUMI T,et al.Internationalconsensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J].Thromb Haemost,2006,4 (2):295-306.
7[2]P.G.DE GROOT,R.H.W.M.DERKSEN.Pathophysiology of antiphospholipid antibodies[J].The Netherlands journal of medicine,2004,62 (8):267-272.
8[3]JANINE J.J.HULSTEIN,PETER J,et al.Beta2-Glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation[J].Blood,2007,110 (5):1483-1491.
9[4]YASUDA S,ATSUMI T,IEKO M,et al.Nicked beta 2-glycoprotein I:a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis[J].Blood,2004,103 (10):3766-3772.
10[5]GALLI M,LUCIANI D,BERTOLINI G,et al.Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome:a systematic review of the literature[J].Blood,2003,101 (5):1827-1832.
